ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 645

An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis

Eric Gracey1,2, Melissa Lim2, Zoya Qaiyum1, Yuriy Baglaenko1,2, Wenyan Miao3, Craig Masse3, William Westlin3 and Robert D Inman1,4, 1Department of Immunology, University of Toronto, Toronto, ON, Canada, 2Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3Nimbus Therapeutics, Cambridge, MA, 4Toronto Western Hospital, University Health Network, toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Ankylosing spondylitis (AS) and spondylarthropathy, IL-23, Janus kinase (JAK), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling molecules, was the first JAK to be associated with AS in genome-wide association studies. Tyk2 plays a crucial role in Th17 cell function through mediating IL-23 intracellular signaling, making Tyk2 an attractive target for the treatment of AS. Here we examine the expression of Tyk2 at the cellular level in human peripheral blood mononuclear cells (PBMCs) for evidence of SNP-mediated changes in expression. We further tested a novel, potent and selective Tyk2 inhibitor, NDI-031407, for therapeutic effect in the SKG mouse model of AS.   

Methods:

Flow cytometry on PBMC was carried out on 76 AS patients, 47 healthy controls and 21 RA patients. Tyk2 mRNA was assessed in unstimulated cells using PrimeFlow and cytokines were assessed in PMA/ionomycin-stimulated cells. SKG mice were gavaged twice daily with NDI-031407 or methylcellulose vehicle from weeks 1 to 8 post-disease induction. Mice were scored weekly for clinical presence of peripheral and axial arthritis, dermatitis and blepharitis. Sacroiliitis was assessed by T1- and T2-weighted MRI. Histology was assessed by H&E staining. Th17 frequency and phenotype were assessed by flow cytometry in popliteal, mesenteric and sciatic lymph nodes.

Results:

Tyk2 mRNA expression in PBMCs by flow cytometry did not demonstrate significant differences between AS and controls.  Tyk2 expression levels did not stratify by candidate SNPs (rs12720356, rs35164067) and did not correlate with Th17 frequency. NDI-031407 is a small molecule Tyk2 inhibitor that inhibits Tyk2 with a Ki of 0.2 nM, and is 218-, 148-, and 20-fold selective against JAK1, JAK2, and JAK3, respectively. In SKG mice, therapeutic dosing with NDI-031407 significantly reduced the clinical scores of joint and skin inflammation to normal levels (see figure). MRI of the sacroiliac joint (SIJ) showed joint space narrowing and edema with disease progression and NDI-031407 protected against these SIJ changes. Enthesitis and bone erosion in the ankle and tail were prevented by Tyk2 inhibition. FACS showed that NDI-031407 suppressed the expansion of IL-17A+ Th17 cells (vehicle vs NDI-031407; 6.04% vs 2.73% of CD4+ T cells, p=<0.001) in addition to reducing IL-17F, IL-22, ICOS and Ki67 expression.

Conclusion:

AS-associated Tyk2 SNPs do not impart a difference in Tyk2 expression and likely contribute to AS through promoting Th17 cell function. Our findings indicate that Tyk2 inhibition can prevent disease progression in SKG mice by reducing Th17 cells and associated inflammatory cytokines. Future studies aim to unravel the role of Tyk2 in Th17 cell development to better understand the mechanism behind Tyk2 inhibition. This work provides the first evidence that Tyk2 inhibition presents as a viable therapeutic target in AS.

  


Disclosure: E. Gracey, None; M. Lim, None; Z. Qaiyum, None; Y. Baglaenko, None; W. Miao, None; C. Masse, None; W. Westlin, None; R. D. Inman, None.

To cite this abstract in AMA style:

Gracey E, Lim M, Qaiyum Z, Baglaenko Y, Miao W, Masse C, Westlin W, Inman RD. An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/an-oral-tyk2-inhibitor-effectively-suppresses-the-development-of-murine-th17-cells-in-vivo-and-prevents-joint-damage-in-experimental-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-oral-tyk2-inhibitor-effectively-suppresses-the-development-of-murine-th17-cells-in-vivo-and-prevents-joint-damage-in-experimental-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology